Biotech Index Shifts
Russell Index Reconstitution Moves Vertex Pharma to Value, Reshaping Biotech Portfolios
Key Points
Roivant Sciences’ removal from the Russell 1000 Defensive Index is discussed alongside Marketscreener’s composite rating approach, which aggregates four metrics—Returns, Profitability, Quality of Financial Reporting, and Financial Health—and notes a rating calculation requires coverage by at least two of these criteria.
Vertex Pharmaceuticals was added to the Russell 1000 Value Index while being dropped from the Russell 1000 Growth Index, highlighting a shift in its style classification for large-cap portfolios.
The Reuters/MarketScreener reports emphasize that the Russell 1000 Value and Growth indices are widely followed by institutional investors, meaning Vertex’s reclassification could influence passive fund flows and benchmark-driven active management.
Novavax was dropped from the Russell 3000E Growth benchmark as part of routine Russell reconstitutions that continue reshaping growth-oriented coverage within the Russell family.
Vertex Pharmaceuticals has been moved into the Russell 1000 Value Index and removed from the Russell 1000 Growth Index as part of the 2024 FTSE Russell annual reconstitution, according to MarketScreener. The reclassification marks a turning point for one of biotech's biggest names — and signals that Vertex's era as a pure growth stock is officially over in the eyes of index compilers.
The shift affects roughly $10.5 trillion in assets benchmarked to Russell US indices, according to LSEG. Passive funds tracking the Russell 1000 Growth index — such as BlackRock's IWF — were forced sellers of Vertex shares. Value-oriented funds like IWD became forced buyers. That kind of mechanical rebalancing typically moves billions of dollars on a single trading day.
How a $11 Billion Revenue Year Lands You in Value
Vertex reported full-year 2024 product revenue of $11.02 billion — a 12% increase year over year, according to Business Wire. That sounds like growth. But FTSE Russell uses three mechanical inputs to sort stocks: price-to-book ratio, forecast medium-term earnings growth, and five-year historical sales growth. As Vertex's dominant cystic fibrosis franchise matured, those numbers looked less like a fast-growing biotech and more like a steady, cash-generating business.
The so-called "Magnificent Seven" effect also played a role, according to LSEG. Mega-cap tech stocks like Nvidia and Microsoft consume so much of the Growth index that other large-caps with solid — but not explosive — growth get pushed into Value to maintain Russell's required 50/50 split. Vertex got caught in that squeeze. FTSE Russell Director Catherine Yoshimoto said the annual recalibration is "critical to ensure the indexes accurately reflect company size and style shifts."
Roivant and Novavax Also Reshuffled Out of Key Benchmarks
Vertex was not the only biotech reclassified. Roivant Sciences was dropped from the Russell 1000 Defensive Index, according to MarketScreener. The move highlights a debate about what "defensive" means in biotech. Roivant held over $4.9 billion in cash but posted net losses of roughly $300 million in 2024. That kind of inconsistent profitability tends to disqualify a stock from low-volatility defensive indices, which favor steady, high-quality earners.
Novavax was dropped from the Russell 3000E Growth benchmark, according to GuruFocus. Its market cap collapsed from over $20 billion at its 2021 peak to roughly $1.39 billion by mid-2024 — a direct result of falling COVID-19 vaccine demand. Analysts at Jefferies noted that a deal with Sanofi "significantly de-risked" Novavax, but the market remains cautious about its long-term growth story.
Value Label Doesn't Mean Vertex Has Stopped Growing
Analysts at Truist Securities and RBC Capital were quick to separate the index label from the business reality. Truist initiated a "Buy" rating on Vertex with a $542 price target during the reconstitution period, according to MarketBeat. Its pipeline includes suzetrigine, a non-opioid pain drug, and povetacicept for kidney disease — both potential blockbusters. The message from Wall Street: "Value" in an index context does not mean stagnant.
MFS Investment Management analysts warned investors that index style shifts are "mechanical" and do not always reflect the forward-looking intent of the company. Vertex CEO Reshma Kewalramani, M.D., has positioned the firm around a multi-disease platform, not just cystic fibrosis. Being labeled "Value" by an algorithm changes who owns the stock — it does not change what the company is building.
Annual Reconstitution Creates Billions in Forced Trades — But Change Is Coming
The 2024 reconstitution was finalized at the close of U.S. markets on June 28, 2024, with the new index composition taking effect July 1. That single session is one of the highest-volume trading days of the year. Over $134 billion typically changes hands in the final minutes of "Recon Day" alone, according to LSEG. The entire U.S. investable equity market was valued at $53.0 trillion on April 30, 2024 — up 20% from the prior year.
The annual "Big Bang" reconstitution will not last forever. FTSE Russell announced that starting in 2026, it will shift to a semi-annual schedule — rebalancing in both June and December — to reduce the volatility spike that comes with a single yearly event, according to LSEG. For large-cap biotech investors, that means index-driven reclassifications like Vertex's could happen twice a year going forward.
Sentiment
Mostly PositivePublishers
10
Articles
54
Reach
64
